Clinical information
Diagnostic utility:
It is based on the confirmatory detection of IgG antibodies against the hepatitis C virus (HCV). The assay uses antigens derived from the Core region, the Hypervariable Region E2 (HVR), the NS3 Helicase (NS3), NS4A, NS4B, and NS5A of the HCV. The technique is useful for:
- Confirmation of HCV antibodies in individuals with chronic infection or resolved infection spontaneously or through antiviral treatment.
Method:
Immunoblot assay.
Reference values
Possible results are: Reactive, Non-reactive, and Indeterminate.
Diagnostic algorithm:
Not applicable.
Turnaround time:
Maximum 15 working days
Specimen information
Sample: Serum and/or plasma
Tube: Aliquots of 1-5 mL, plasma tubes with citrate, heparin, or EDTA as anticoagulant and/or serum tubes with and without gel separator.
Minimum essential volume: 1 ml
Stability:
- At room temperature: ≤ 4 days
- In refrigeration 2-8 ºC: ≤ 7 days
- Sample frozen equal to or less than -20ºC: 10 years
Transport instructions: Preferably at room temperature and/or refrigerated if they are total blood tubes, and frozen if they are serum and/or plasma aliquots.
Reason for rejection: Highly hemolyzed sample.
Administrative information
BST Code: 0124
Test Description: Hepatitis C, IgG Antibodies. Confirmation by Immunoblot.
Synonyms: anti-HCV
Section: Transfusion Safety Laboratory
BST Rates: Consult the updated rates here.
Profiles:
N/A.
References
- Insert INNO-LIA HCV Score de Fujirebio.
Quality
BST holds ISO 9001, ISO 14001, and OSHAS 18001 quality certifications, as well as the European Excellence 500+ seal. BST is accredited by CAT, JACIE-FACT, FACT-NETCORD, and EFI, and complies with Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) guidelines.